ライフサイエンスコーパス: fibrinolytic therapy

1 dosing unfractionated heparin in support of fibrinolytic therapy.

2 >1 hour beyond door-to-needle (DN) times for fibrinolytic therapy.

3 0.64; P=0.006) but not in those treated with fibrinolytic therapy.

4 fer for direct PCI may also be preferable to fibrinolytic therapy.

5 s aged older than 70 years or in those given fibrinolytic therapy.

6 ents are used with standard- or reduced-dose fibrinolytic therapy.

7 ry intervention institutions or who received fibrinolytic therapy.

8 apies and faster time intervals from door to fibrinolytic therapy (12.1 minutes faster, P<0.001) or t

9 door-to-needle times for patients receiving fibrinolytic therapy (19 min vs. 29 min, p = 0.003) and

10 Patients (73,032 receiving fibrinolytic therapy; 37,143 receiving primary percutane

11 Most patients with STEMI receive fibrinolytic therapy and aspirin.

12 use of thoracentesis, chest tube placement, fibrinolytic therapy and open thoracotomy in children wi

13 als have supported the potential of combined fibrinolytic therapy and platelet glycoprotein IIb/IIIa

14 ctive therapy in STEMI patients treated with fibrinolytic therapy and subsequent PCI.

15 on myocardial infarction (STEMI) who receive fibrinolytic therapy and subsequently undergo percutaneo

16 visual outcomes after CRAO (with or without fibrinolytic therapy) and a series of more than 5 patien

17 rent standard interventions (eg, aspirin and fibrinolytic therapy), and the balance of potential bene

18 the 1st (P =.001) and 2nd (P =.002) days of fibrinolytic therapy, and for the duration of thoracosto

19 rdial infarction with thrombus aspiration or fibrinolytic therapy, and postmortem pathological observ

20 ; the determination of prognosis early after fibrinolytic therapy; and the use of ST segment resoluti

21 symptom onset who had not received previous fibrinolytic therapy, anticoagulants, or glycoprotein II

22 primary PCI and 14 332 patients who received fibrinolytic therapy at 444 PCI-capable hospitals.

23 patient as compared with providing immediate fibrinolytic therapy at their initial hospital; yet more

24 TEMI), or they may selectively offer PPCI or fibrinolytic therapy based on patient and hospital-level

25 al contact-to-needle) time for initiation of fibrinolytic therapy can be achieved within 30 min or do

26 re-hospital ECG was performed in 4.5% of the fibrinolytic therapy cohort and in 8.0% of the PCI cohor

27 In 1999, only 46% of the patients in the fibrinolytic therapy cohort were treated within the reco

28 ey to successful treatment, but intrapleural fibrinolytic therapy did not improve outcomes in an earl

29 The benefits of fibrinolytic therapy diminish in patients presenting wit

30 nts experience significantly longer times to fibrinolytic therapy (door-to-drug times) and percutaneo

31 icant occult fibrin burden and suggests that fibrinolytic therapy during NESLiP may be a promising th

32 ays should prompt increased consideration of fibrinolytic therapy, emergency medical services hospita

33 rvention and to promote the selective use of fibrinolytic therapy, especially prehospital fibrinolysi

34 The strategy of ENOX support for fibrinolytic therapy followed by PCI is superior to UFH

35 Patients receiving fibrinolytic therapy for acute MI admitted to hospitals

36 Fibrinolytic therapy for acute myocardial infarction, ev

37 assessing reperfusion in patients receiving fibrinolytic therapy for acute ST elevation myocardial i

38 ests that a clinical trial of early systemic fibrinolytic therapy for CRAO is warranted and that cons

39 substantial proportion of patients receiving fibrinolytic therapy for myocardial infarction with ST-s

40 bridging therapies, role of aspirin, use of fibrinolytic therapy for prosthetic valve thrombosis, an

41 epicardial flow among patients treated with fibrinolytic therapy for ST-segment elevation myocardial

42 RS <0% following rescue/adjunctive PCI after fibrinolytic therapy for STEMI was independently associa

43 Among patients treated with fibrinolytic therapy for STEMI who underwent subsequent

44 Although early recurrent MI after fibrinolytic therapy has been associated with increased

45 Although the use of fibrinolytic therapy has progressively decreased over th

46 ry angioplasty provides outcomes superior to fibrinolytic therapy in AMI, but its use in community ho

47 ovides any propitious benefits over standard fibrinolytic therapy in diabetic patients.

48 cute myocardial infarction (MI) treated with fibrinolytic therapy in hospitals with and without coron

49 The role of fibrinolytic therapy in patients with intermediate-risk

50 onary intervention (PCI) capability also use fibrinolytic therapy in patients with ST-segment elevati

51 Although fibrinolytic therapy in patients with ST-segment elevati

52 on of glycoprotein IIb or IIIa inhibitors to fibrinolytic therapy increased the risk of major bleedin

53 mized clinical trials comparing intrapleural fibrinolytic therapy (IPFT) with surgical decortication

54 imary PCI leads to better outcomes than when fibrinolytic therapy is administered at community hospit

55 rdial infarction (STEMI) patients undergoing fibrinolytic therapy is associated with adverse outcomes

56 ns difficult to implement in many areas, and fibrinolytic therapy is still widely used.

57 BEST PRACTICE ADVICE 8: Anti-fibrinolytic therapy may be considered in patients with

58 e and importance of the prompt, early use of fibrinolytic therapy may be underappreciated.

59 Since routine fibrinolytic therapy may decrease these complications, t

60 k who received acute reperfusion with either fibrinolytic therapy (n = 35,370) or primary percutaneou

61 n patients admitted with STEMI and receiving fibrinolytic therapy (n = 68,439 patients in 1,015 hospi

62 ry intervention (PPCI) is superior to onsite fibrinolytic therapy (O-FT) when administered in a timel

63 myocardial infarction is superior to onsite fibrinolytic therapy (O-FT), the generalizability of the

64 Fibrinolytic therapy offers an alternative to mechanical

65 Fibrinolytic therapy plays a pivotal role in the managem

66 s with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensatio

67 tion myocardial infarction (STEMI) receiving fibrinolytic therapy remains under study.

68 ours of presentation reduces mortality, with fibrinolytic therapy reserved for patients without acces

69 After adjustment for age, fibrinolytic therapy, revascularization, region, and ele

70 pirin and other standard treatments (such as fibrinolytic therapy) safely reduces mortality and major

71 on of glycoprotein IIb or IIIa inhibitors to fibrinolytic therapy should be discouraged.

72 the advantage of this strategy over on-site fibrinolytic therapy that has been demonstrated in recen

73 In patients with STEMI receiving fibrinolytic therapy, the net benefit of ENOX is similar

74 ay result in superior outcomes compared with fibrinolytic therapy, the performance of primary angiopl

75 for primary PCI may be superior to immediate fibrinolytic therapy, these findings are unlikely to gen

76 In patients with STEMI receiving fibrinolytic therapy, use of LMWH with other standard th

77 ersus 86.3% with an in-hospital ECG, whereas fibrinolytic therapy was used in 4.6% versus 4.2% of pat

78 total of 20,479 STEMI patients who received fibrinolytic therapy were randomized to a strategy of EN

79 sk factors for intracranial hemorrhage after fibrinolytic therapy, were not associated with increased

80 If PCI within 120 minutes is not possible, fibrinolytic therapy with alteplase, reteplase, or tenec

81 tion myocardial infarction (STEMI) receiving fibrinolytic therapy with and without clopidogrel.

82 ly assigned to undergo either primary PCI or fibrinolytic therapy with bolus tenecteplase (amended to

83 t reduce mortality over 1 year compared with fibrinolytic therapy with reteplase alone.

84 icant proportion of patients to the risks of fibrinolytic therapy without the likelihood of significa